Cancer Forums and News by PhD's

News | Forums

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News


Cancer Review


Recent Forum Topics

Novel drug combo improves breast cancer survival
By gdpawel at 2009-12-13 21:56

SAN ANTONIO -- Some women with very advanced breast cancer may have a new treatment option. A combination of two drugs that more precisely target tumors significantly extended the lives of women who had stopped responding to other medicines, doctors reported Friday.

It was the first big test of combining Herceptin and Tykerbterm. In a study of 300 patients, women receiving both drugs lived nearly five months longer than those given Tykerb alone.

read more | 1523 reads

Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Can
By Dross at 2008-01-16 01:41

Kosan Biosciences Incorporated (NASDAQ:KOSN) today announced the initiation of a Phase 2 trial of alvespimycin, the company's second-generation Hsp90 inhibitor, in patients with HER2-positive metastaticterm breast cancer. Alvespimycin has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2, a key signaling pathway in breast cancer. The objective of the Phase 2 trial is to evaluate the safety and anticancer activity of alvespimycin as a single agent in patients who have not previously received Herceptin for metastatic disease except in an adjuvant setting. Antitumor data in patients with advanced HER2-positive cancer presented at the September 2007 American Society of Oncology (ASCO) Breast Cancer Symposium demonstrated encouraging antitumor activity of alvespimycin in combination with trastuzumab (Herceptin(R)).

read more | 1419 reads

Mayo Clinic - Even Tiny Breast Tumors Can Be Aggressive and May Require Maximum Therapy
By Dross at 2007-12-17 22:07

SAN ANTONIO — Breast tumors that are 1 centimeter in size or smaller — no more than 0.4 inch in length — can still be very aggressive and may require more intensive therapy than is routinely offered today, say researchers at Mayo Clinic in Jacksonville, Fla.

The study, which is being presented at the San Antonio Breast Cancer Symposium, is one of the few that has looked at outcomes of women who have tiny tumors that have not spread to the lymph nodes. The findings suggest that outcome of two types of breast cancer — those classified as HER2 positive (HER2+) and triple negative — may not depend on size alone.

read more | 2891 reads

Herceptin does not increase heart failure in patients long-term
By Dross at 2007-06-04 00:56

CHICAGO, June 3 – Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapyterm for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Based on the findings, the research team developed a prediction model to help oncologists assess the risk of heart failure in individual breast cancer patients prior to treatment with Herceptin and chemotherapy. Their findings will be announced at the Women’s Cancers press briefing at the meeting and published in Abstract LBA513 in the ASCO proceedings.

read more | 1525 reads

Jefferson researchers boost immune 'killer cells,' increase antibody effectiveness against cancer
By Dross at 2007-04-18 22:11

Researchers at the Kimmel Cancer Center at Jefferson in Philadelphia have devised a novel method to expand the number of immune system "natural killer (NK)" cells from blood cells outside the body. They have found that adding such cells to anti-cancer therapies involving monoclonal antibodyterm drugs is more effective in killing cancer cells, and perhaps someday may improve treatments.


Reporting April 18, 2007 at the annual meeting of the American Association for Cancer Research in Los Angeles, scientists led by Takami Sato, M.D., K. Hasumi Associate Professor of Medical Oncology at Jefferson Medical College of Thomas Jefferson University showed in laboratory studies that adding such NK cells to a monoclonal antibody, Herceptin, which targets the HER2/neu protein on breast cancer cells, was more efficient at killing the cancer cells. The HER2/neu protein is expressed in approximately one-quarter of all breast cancers.

read more | 1789 reads

PER.C6 Technology from Crucell Could Soon Herald Lowered Costs for Antibody Treatments
By HCat at 2007-02-21 02:40

    Crucell in a partnership with DSM have announced that production of monoclonal antibodies has reached 10g/L (grams per liter) of cell culture, using the PER.C6 platform to produce the yields. Current standard methods yield monoclonal antibodies around 1-2g/L. This order of magnitude increase in yield could help lower the cost for producing the current monoclonal antibodies used in treatments for cancer today. The price of drugs has soared for cancer treatment and the monoclonal antibodyterm is no exception. Herceptin costs around $3,000 a month, Avastinterm is at $4,400, Erbituxterm costs around $10,000 a month, and Rituxanterm can range from $4,200 to $13,000 a month depending on treatment. A great article on recent drug costs can be found here on the USA Today site.


read more | 3641 reads

Gene profiling predicts resistance to breast cancer drug Herceptin
By Dross at 2007-02-20 23:36

PHILADELPHIA -- Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor. In the February 15 issue of Clinical Cancer Research, the researchers found that HER2-positive tumors that did not respond to Herceptin expressed certain basal markers, growth factors and growth factor receptors. One of these, insulin-growth factor receptor 1(IGF-1R), was associated with a Herceptin response rate that was half that of tumors that did not express IGF-1R. They also discovered that resistant tumors continue to over-express the HER2 growth factor protein -- an important finding given that many scientists had thought that loss of HER2 was likely responsible for Herceptin resistance. "Herceptin has revolutionized the care of HER2-positive breast cancer for many patients, but unfortunately, not for some.

read more | 1 comment | 1427 reads

Patented Technology Could Improve Efficacy of Monoclonal Antibodies
By HCat at 2007-02-06 10:34

    BioWa, Inc has a patented technology platform called Potelligent which modifies monoclonal antibodies so that they have enhanced binding to increase Antibodyterm-dependent cellular cytotoxicity (ADCC). ADCC is the mechanism by which some antibodies can kill cancer cells. Once an antibody binds to a cell, Natural Killer (NK) cells and Monocytes in the immune system attack the bound cell, ultimately killing it.

    UCB biopharmaceutical company has been has been allowed to use Potelligent in order to develop new antibodies toward novel targets. The enhanced ADCC could help bring new antibodies to market that have greater efficacy while possibly lowering production costs of the treatment. Erbituxterm and Herceptin are antibodies whose efficacy is dependent on ADCC.

read more | 3345 reads

FDA Approves Herceptin(R) for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer
By admin at 2006-11-18 05:44
Only Targeted Biologic Therapy Approved for Use in Adjuvant and Metastatic HER2-positive Breast Cancer -

SOUTH SAN FRANCISCO, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE-DNA) announced today that the U.S. Food and Drug Administration (FDA) approved Herceptin(R) (Trastuzumab), as part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel, for the adjuvant treatment of HER2-positive node-positive breast cancer. Adjuvant therapy is given to women with early-stage (localized) breast cancer who have had initial treatment - surgery with or without radiation therapy - with the goal of reducing the risk of cancer recurrence and/or the occurrence of metastatic disease.
read more | 2931 reads

Syndicate content

sponsored links



Subscribe to our newsletter to receive info on our site or upcoming clinical trials

Confirm your email address

HTML format

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate

Syndicate content

All times are GMT -5. The time now is 03:31 PM.